Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $21,150.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 846 shares of CeriBell stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $25.00, for a total transaction of $21,150.00. Following the completion of the sale, the chief financial officer directly owned 146,600 shares of the company’s stock, valued at approximately $3,665,000. The trade was a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, September 2nd, Scott Blumberg sold 652 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $16,300.00.
• On Friday, August 21st, Scott Blumberg sold 1,521 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $36,534.42.
• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total transaction of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Stock Performance

CBLL traded up $0.50 during trading on Thursday, hitting $25.00. 734,947 shares of the company traded hands, compared to its average volume of 280,012. CeriBell, Inc. has a one year low of $10.85 and a one year high of $25.63. The stock’s fifty day moving average is $21.51 and its 200 day moving average is $19.79. The firm has a market cap of $959.50 million, a P/E ratio of -14.20 and a beta of 0.95. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The company had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. As a group, equities analysts predict that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Raymond James Financial reissued a “strong-buy” rating and set a $29.00 price objective on shares of CeriBell in a report on Thursday, September 3rd. Canaccord Genuity Group upped their price objective on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Finally, BTIG Research reaffirmed a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research note on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.40.

Institutional Trading of CeriBell

A number of institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of CeriBell in the second quarter worth $37,657,000. KCM Capital Inc boosted its holdings in shares of CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after buying an additional 400,000 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of CeriBell during the 2nd quarter valued at $17,437,000. TimesSquare Capital Management LLC purchased a new stake in CeriBell in the second quarter worth about $15,182,000. Finally, Royce & Associates LP purchased a new stake in CeriBell in the 4th quarter worth approximately $11,695,000.

CeriBell Company Profile

Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.